ARTICLE | Company News
TaiGen, Zhejiang Medicine sales and marketing update
July 2, 2012 7:00 AM UTC
TaiGen granted Zhejiang Medicine exclusive rights to commercialize and manufacture nemonoxacin in China, excluding Hong Kong and Macau. TaiGen will receive an $8 million upfront payment and is eligib...